| Systemic Lupus Erythematosus |
1 |
1 |
| Lupus |
0 |
0.89 |
| Cutaneous Lupus Erythematosus |
0 |
0.8 |
| Discoid Lupus Erythematosus |
0 |
0.67 |
| Biologic Therapy |
0 |
0.2 |
| Severity Index |
0 |
0.18 |
| Humanized Monoclonal Antibody |
0 |
0.13 |
| Monoclonal Antibody |
0 |
0.12 |
| Pathogenesis |
0 |
0.12 |
| Pennsylvania |
0 |
0.12 |
| Receptors |
0 |
0.12 |
| Herpes Zoster |
0 |
0.11 |
| Patient Safety |
0 |
0.09 |
| Connective Tissue Disease |
0 |
0.08 |
| Adverse Effects |
0 |
0.06 |
| Antigens |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Chemokines |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Cytokines |
0 |
0.06 |
| Dermatoses |
0 |
0.06 |
| Environmental Medicine |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Inpatient Care |
0 |
0.06 |
| Meningitis |
0 |
0.06 |
| New York |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.05 |
| Meningococcal Disease |
0 |
0.05 |